Hookipa Pharma (NASDAQ:HOOK) Earns “Outperform” Rating from Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $5.00 price objective on the stock.

Separately, HC Wainwright lowered their price target on Hookipa Pharma from $6.50 to $5.00 and set a buy rating on the stock in a research report on Friday, April 26th.

Hookipa Pharma Trading Up 6.1 %

Shares of NASDAQ HOOK opened at $1.04 on Tuesday. The business has a 50-day moving average of $0.80 and a 200-day moving average of $0.71. The firm has a market capitalization of $102.91 million, a price-to-earnings ratio of -2.08 and a beta of 0.92. Hookipa Pharma has a 12 month low of $0.41 and a 12 month high of $1.50.

Hookipa Pharma (NASDAQ:HOOK) last released its quarterly earnings results on Thursday, May 9th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.24. The business had revenue of $36.60 million during the quarter, compared to analysts’ expectations of $3.20 million. Hookipa Pharma had a negative net margin of 88.73% and a negative return on equity of 33.33%. During the same quarter in the previous year, the company earned ($0.27) EPS. On average, analysts predict that Hookipa Pharma will post -0.53 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hookipa Pharma stock. Virtu Financial LLC bought a new position in Hookipa Pharma Inc (NASDAQ:HOOK) during the first quarter, according to the company in its most recent filing with the SEC. The firm bought 43,021 shares of the company’s stock, valued at approximately $31,000. Institutional investors own 63.88% of the company’s stock.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.